Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599647 | 1.00 | KLK7 (0.41) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598151 | 1.00 | KLK7 (0.41) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL1908590 | 0.88 | L3MBTL1 (0.37) | ATML3MBTL1CCR5 | |
| SCHEMBL597038 | 0.88 | L3MBTL1 (0.37) | ATML3MBTL1CCR5 | |
| SCHEMBL598277 | 0.88 | L3MBTL1 (0.37) | ATML3MBTL1CCR5 | |
| SCHEMBL11993549 | 0.85 | KLK7 (0.43) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL18922324 | 0.78 | KLK7 (0.39) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598408 | 0.75 | FASN (0.35) | CCR5 | |
| SCHEMBL597903 | 0.75 | FASN (0.35) | CCR5 | |
| SCHEMBL1908592 | 0.75 | FASN (0.35) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | disclosed |
| US-8993785-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8716495-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20140249320-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
| US-20150166468-A1 | Process for Preparing 5-biphenyl-4-amino-2-methyl Pentanoic Acid | MME, REN, PAH | KLK7 3403/4885KLK5 1873/4885PRSS1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.